ArticleBMC microbiology2020
Resveratrol enhances the antimicrobial effect of polymyxin B on Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance.
Article in BMC microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Effects of Nasal Solution Incorporating Resveratrol and Carboxymethyl-Β-Glucan in Preschool Non-Atopic Children with Wheezing.Nutrients · 2024Trial
- Antimicrobial Strategies in the Era of Resistance: It Is Too Early to Give Up Antibiotic Therapy.International journal of molecular sciences · 2026Review
- Dual action of herbal compounds inFrontiers in immunology · 2026Review
- Investigation of antimicrobial synergism of actinomycin derivatives fromTurkish journal of biology = Turk biyoloji dergisi · 2026Article
- A Critical Review of Quorum-Sensing Inhibition Strategies in Klebsiella Pneumoniae.Current microbiology · 2025Review
- Synergistic Interactions Between Natural Phenolic Compounds and Antibiotics Against Multidrug-ResistantMicroorganisms · 2025Article
- Forging a New Frontier: Antimicrobial Peptides and Nanotechnology Converging to Conquer Gastrointestinal Pathogens.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Antibacterial and Antibiofilm Activities of Hydralazine, an Antihypertensive Drug: In Vitro and In Silico Approaches.Antibiotics (Basel, Switzerland) · 2025Article
- Emerging Applications of Plant Antimicrobials in the Food Industry.Current pharmaceutical biotechnology · 2025Review
- Effectiveness of Yinhua Pinggan granules in community-acquired pneumonia: a randomized, double-blind clinical trial.Frontiers in pharmacology · 2025Article
- Antimicrobial proteins from oyster hemolymph improve the efficacy of conventional antibiotics.PloS one · 2025Article
- Antibacterial phenolic compounds from the flowering plants of Asia and the Pacific: coming to the light.Pharmaceutical biology · 2024Review
- Protective and Detoxifying Effects of Resveratrol on Zearalenone-Mediated Toxicity: A Review.International journal of molecular sciences · 2024Review
- Inhibition of the ATP synthase increases sensitivity of Escherichia coli carrying mcr-1 to polymyxin B.The Journal of antibiotics · 2024Article
- Potential of Resveratrol to Combine with Hydrogel for Photodynamic Therapy against Bacteria and Cancer-A Review.Biomedicines · 2024Review
- [Research progress on the role of resveratrol in wound healing].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2024Review
- The Antimicrobial Potential of the Hop (Pharmaceuticals (Basel, Switzerland) · 2024Article
- Peptide Antibiotic-Polyphosphate Nanoparticles: A Promising Strategy to Overcome the Enzymatic and Mucus Barrier of the Intestine.Biomacromolecules · 2023Article
- Phytochemicals as Invaluable Sources of Potent Antimicrobial Agents to Combat Antibiotic Resistance.Life (Basel, Switzerland) · 2023Review
- Polymyxin B and fusidic acid, a novel potent synergistic combination againstFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMultidrug resistant (MDR) Gram-negative bacterial infections are a serious threat to human health due to the lack of effective treatments. In this study, we selected 50 Gram-negative bacterial strains, including 26 strains of Klebsiella pneumoniae and 24 strains of Escherichia coli, to explore whether resveratrol and polymyxin B have a synergistic killing effect.
resultsMIC values against polymyxin B were ≥ 4 μg/mL for 44 of the strains and were 2 μg/mL for the other 6 strains. MICs against polymyxin B in the isolates tested were significantly reduced by the addition of resveratrol. The degree of decline depended on the bacteria, ranging from 1/2 MIC to 1/512 MIC, and the higher the concentration of resveratrol, the greater the decrease. Checkerboard analysis indicated a synergistic effect between resveratrol and polymyxin B; the optimal drug concentration for different bacteria was different, that of resveratrol ranging from 32 μg/mL to 128 μg/mL. Subsequent time-kill experiments showed that a combination of polymyxin B and resveratrol was more effective in killing bacteria.
conclusionsOur in vitro studies have shown that resveratrol can increase the sensitivity of MDR bacterial strains to polymyxin B, suggesting a potential new approach to the treatment of MDR infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.